Open AccessAflibercept – a novel agent for VEGF‐driven macular disease
Author(s) -
Morphis George
Publication year - 2012
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.95
Subject(s) - aflibercept , medicine , food and drug administration , macular degeneration , ranibizumab , vegf receptors , adverse effect , drug , ophthalmology , vascular endothelial growth factor , george (robot) , pharmacology , bevacizumab , artificial intelligence , chemotherapy , computer science
Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age‐related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.